<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03851939</url>
  </required_header>
  <id_info>
    <org_study_id>B2018-158-01</org_study_id>
    <nct_id>NCT03851939</nct_id>
  </id_info>
  <brief_title>The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC): A Prospective, Single-armed, Stage II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the efficacy of TAI combine toripalimab in advanced HCC.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 26, 2019</start_date>
  <completion_date type="Anticipated">March 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PFS</measure>
    <time_frame>From date of randomization until the date of progression, assessed up to 36 months</time_frame>
    <description>progression-free survival</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR</measure>
    <time_frame>From date of randomization until the date of death, assessed up to 36 months</time_frame>
    <description>objective response rate</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>OS</measure>
    <time_frame>From date of randomization until the date of death from any cause, assessed up to 36 months</time_frame>
    <description>overall survival</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DCR</measure>
    <time_frame>From date of randomization until the date of death, assessed up to 36 months</time_frame>
    <description>disease control rate</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">65</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Transarterial Chemoinfusion (TAI) Combine Toripalimab</description>
  </arm_group>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Transarterial Chemoinfusion (TAI) Combine Toripalimab</intervention_name>
    <description>Transarterial Chemoinfusion (TAI) Combine Toripalimab</description>
    <arm_group_label>treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  older than 18 years old and younger than 75 years;

          -  ECOG PS≤1;

          -  proven advanced hepatocellular carcinoma according patological examination or
             EASL/AASLD diagnostic criteria;

          -  not previous treated for tumor;

          -  cannot accepted hepatectomy;

          -  the lab test could meet:

               -  neutrophil count≥2.0×109/L;

               -  hemoglobin≥100g/L;

               -  platelet count≥75×109/L;

               -  serum albumin≥35g/L;

               -  total bilirubin&lt;2-times upper limit of normal;

               -  ALT&lt;3-times upper limit of normal;

               -  AST&lt;3-times upper limit of normal;

               -  serum creatine&lt;1.5-times upper limit of normal;

               -  PT≤upper limit of normal plus 4 seconds;

               -  INR≤2.2;

          -  sign up consent;

        Exclusion Criteria:

          -  cannot tolerate TAI or toripalimab;

          -  known history of other malignancy;

          -  be allergic to related drugs;

          -  underwent organ transplantation before;

          -  be treated before (interferon included);

          -  known history of HIV infection;

          -  known history of drug or alcohol abuse;

          -  have GI hemorrhage or cardiac/brain vascular events within 30 days;

          -  pregnancy;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Shaohua Li, MD</last_name>
    <phone>+8615088064187</phone>
    <email>lishaoh@sysucc.org.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>SUN YAT-SEN University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rong-Ping Guo, M.D.</last_name>
      <phone>00862087342266</phone>
      <email>guorp@sysucc.org.cn</email>
    </contact>
    <contact_backup>
      <last_name>Wei Wei, Ph.D. M.D.</last_name>
      <phone>00862087343790</phone>
      <email>weiwei@sysucc.org.cn</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>February 21, 2019</study_first_submitted>
  <study_first_submitted_qc>February 21, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 22, 2019</study_first_posted>
  <last_update_submitted>February 21, 2019</last_update_submitted>
  <last_update_submitted_qc>February 21, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Rong-ping Guo</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

